Novartis Bets On Buybacks Due To Limited M&A Options
Unveils Another $15bn Share Repurchasing Program
Chief financial officer Harry Kirsch has told reporters that decent bolt-on acquisition opportunities are rare and in their absence, buybacks represent a sensible use of capital.
